Home > Gastroenterology > Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma

Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma

Presented By
Dr Chigusa Morizane, National Cancer Center Hospital, Japan
Conference
ASCO GI 2022
Trial
Phase 3, JCOG1213, TOPIC-NEC
Etoposide and irinotecan showed equal efficacy in a head-to-head study among patients with advanced neuroendocrine carcinoma (NEC) of the digestive system [1]. Therefore, these agents both remain first-line therapeutic options for this population. “Platinum-based chemotherapy regimens are recommended for advanced NEC,” said Dr Chigusa Morizane (National Cancer Center Hospital, Japan). “Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are standard-of-care options for patients with this condition. However, it is currently unknown which combination is more effective.” Therefore, the phase 3 TOPIC-NEC study (UMIN000014795) was designed to compare EP and IP head-to-head in patients with advanced NEC (n=170). The patients were randomised 1:1 to either EP: etoposide (100 mg/mg2, day 1, 2, 3) and cisplatin (80 mg/m2, day ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on